Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
Vivek Narayan, Naomi Balzer Haas Division of Hematology/Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-03-01
|
| Series: | International Journal of Nephrology and Renovascular Disease |
| Subjects: | |
| Online Access: | https://www.dovepress.com/axitinib-in-the-treatment-of-renal-cell-carcinoma-patient-selection-an-peer-reviewed-article-IJNRD |
| _version_ | 1818295178897653760 |
|---|---|
| author | Narayan V Haas NB |
| author_facet | Narayan V Haas NB |
| author_sort | Narayan V |
| collection | DOAJ |
| description | Vivek Narayan, Naomi Balzer Haas Division of Hematology/Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the second-line treatment setting. However, given the variety of available targeted therapies for mRCC, appropriate patient selection for the available therapies remains a significant clinical challenge. Purpose: This review summarizes the available evidence on the clinical, toxicity, and pharmacologic considerations for determining appropriate patient selection for axitinib therapy. In addition, it describes recent data on the use of predictive biomarkers to guide clinical management. This paper consists of material obtained via PubMed and Medline literature searches through October 2015. Conclusion: Axitinib has a well-established role in the management of mRCC. Consistent clinical efficacy has been demonstrated across prognostic risk groups and prior therapeutic exposures. Although axitinib is generally well tolerated, appropriate toxicity management is critical to maximizing drug delivery and optimizing treatment outcomes. Although incident hypertension has been associated with improved clinical outcomes on axitinib, there are currently no validated clinical or genetic predictive biomarkers to guide patient selection. Keywords: axitinib, vascular endothelial growth factor receptor, renal cell carcinoma, predictive marker |
| first_indexed | 2024-12-13T03:43:31Z |
| format | Article |
| id | doaj.art-e9b81fc89eee431497dba95541554d18 |
| institution | Directory Open Access Journal |
| issn | 1178-7058 |
| language | English |
| last_indexed | 2024-12-13T03:43:31Z |
| publishDate | 2016-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nephrology and Renovascular Disease |
| spelling | doaj.art-e9b81fc89eee431497dba95541554d182022-12-22T00:00:52ZengDove Medical PressInternational Journal of Nephrology and Renovascular Disease1178-70582016-03-012016Issue 1657226187Axitinib in the treatment of renal cell carcinoma: patient selection and perspectivesNarayan VHaas NBVivek Narayan, Naomi Balzer Haas Division of Hematology/Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the second-line treatment setting. However, given the variety of available targeted therapies for mRCC, appropriate patient selection for the available therapies remains a significant clinical challenge. Purpose: This review summarizes the available evidence on the clinical, toxicity, and pharmacologic considerations for determining appropriate patient selection for axitinib therapy. In addition, it describes recent data on the use of predictive biomarkers to guide clinical management. This paper consists of material obtained via PubMed and Medline literature searches through October 2015. Conclusion: Axitinib has a well-established role in the management of mRCC. Consistent clinical efficacy has been demonstrated across prognostic risk groups and prior therapeutic exposures. Although axitinib is generally well tolerated, appropriate toxicity management is critical to maximizing drug delivery and optimizing treatment outcomes. Although incident hypertension has been associated with improved clinical outcomes on axitinib, there are currently no validated clinical or genetic predictive biomarkers to guide patient selection. Keywords: axitinib, vascular endothelial growth factor receptor, renal cell carcinoma, predictive marker https://www.dovepress.com/axitinib-in-the-treatment-of-renal-cell-carcinoma-patient-selection-an-peer-reviewed-article-IJNRDaxitinibvascular endothelial growth factor receptorrenal cell carcinomapredictive marker |
| spellingShingle | Narayan V Haas NB Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives International Journal of Nephrology and Renovascular Disease axitinib vascular endothelial growth factor receptor renal cell carcinoma predictive marker |
| title | Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives |
| title_full | Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives |
| title_fullStr | Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives |
| title_full_unstemmed | Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives |
| title_short | Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives |
| title_sort | axitinib in the treatment of renal cell carcinoma patient selection and perspectives |
| topic | axitinib vascular endothelial growth factor receptor renal cell carcinoma predictive marker |
| url | https://www.dovepress.com/axitinib-in-the-treatment-of-renal-cell-carcinoma-patient-selection-an-peer-reviewed-article-IJNRD |
| work_keys_str_mv | AT narayanv axitinibinthetreatmentofrenalcellcarcinomapatientselectionandperspectives AT haasnb axitinibinthetreatmentofrenalcellcarcinomapatientselectionandperspectives |